Stockscreener 앱 받기
3.92
2.49%
-0.10
전일 마감가:
$4.02
열려 있는:
$4.01
하루 거래량:
591.87K
Relative Volume:
0.62
시가총액:
$323.66M
수익:
$14.20M
순이익/손실:
$-49.59M
주가수익비율:
-4.6534
EPS:
-0.8424
순현금흐름:
$-35.25M
1주 성능:
-7.33%
1개월 성능:
+0.77%
6개월 성능:
+103.11%
1년 성능:
+250.00%
1일 변동 폭
$3.835
$4.02
1주일 범위
$3.80
$4.39
52주 변동 폭
$1.04
$5.81
Opus Genetics Inc Stock (IRD) Company Profile
명칭
Opus Genetics Inc
전화
248-681-9815
주소
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
3.92 | 323.66M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-03-16 | 개시 | Oppenheimer | Outperform |
| 2026-01-20 | 개시 | BTIG Research | Buy |
| 2025-12-10 | 개시 | B. Riley Securities | Buy |
| 2025-11-25 | 개시 | Piper Sandler | Overweight |
| 2025-10-29 | 개시 | Wedbush | Outperform |
| 2025-10-16 | 개시 | Chardan Capital Markets | Buy |
| 2025-04-11 | 개시 | Craig Hallum | Buy |
| 2024-11-13 | 재개 | H.C. Wainwright | Buy |
모두보기
Opus Genetics Inc 주식(IRD)의 최신 뉴스
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cantor Fitzgerald reiterates Opus Genetics stock rating at Overweight By Investing.com - Investing.com Canada
Price to earnings forward of Opus Genetics, Inc. – NASDAQ:IRD - TradingView
Wedbush Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target Unchanged - TipRanks
Opus Genetics (IRD) Updates on Ongoing Clinical Trial for Eye Di - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: Tenet Healthcare (THC), Opus Genetics (IRD) - The Globe and Mail
Opus Genetics expects September data from gene therapy trial By Investing.com - Investing.com India
Opus Genetics expects September data from gene therapy trial - Investing.com
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results - The Manila Times
Opus Genetics Provides Update on OPGx-BEST1 Phase 1/2 Trial and Expected September Topline Data - Quiver Quantitative
Opus Genetics set to read out BEST1 gene therapy data in September - Stock Titan
Price to earnings forward of Opus Genetics, Inc. – GETTEX:R3X1 - TradingView
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Opus Genetics issues 1-month pediatric gene therapy results - Ophthalmology Times Europe
Price to sales forward of Opus Genetics, Inc. – NASDAQ:IRD - TradingView
Price to book forward of Opus Genetics, Inc. – NASDAQ:IRD - TradingView
Opus Genetics reaches FDA alignment on phase 3 registrational design for OPGx-LCA5 gene therapy - Ophthalmology Times Europe
symbol__ Stock Quote Price and Forecast - CNN
Opus aligns with FDA on rare eye disease gene therapy trial - BioWorld News
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $10 to $13 - Moomoo
IRD Reiterated by BTIG -- Price Target Maintained at $12.00 - GuruFocus
IRD Maintained by Chardan Capital -- Price Target Remains at $13 - GuruFocus
B.Riley reiterates Buy on Opus Genetics stock on FDA alignment By Investing.com - Investing.com South Africa
B.Riley reiterates Buy on Opus Genetics stock on FDA alignment - Investing.com
Opus Genetics stock holds Buy rating at BTIG on gene therapy progress - Investing.com Canada
Opus Genetics aligns with FDA on Phase 3 trial for LCA5 therapy - Investing.com
Opus Genetics Reaches Alignment With US FDA on Phase 3 Trial of OPGx-LCA5 to Treat Retinal Disease - marketscreener.com
Opus Genetics aligns with FDA on Phase 3 trial for LCA5 therapy By Investing.com - Investing.com India
Opus Genetics Reaches FDA Alignment on Phase 3 Design for OPGx-LCA5; BLA May Be Submitted Based on 6-Month Data - Quiver Quantitative
Opus Genetics clears FDA design for Phase 3 trial in childhood blindness - Stock Titan
If You Invested $1,000 in Ocuphire Pharma Inc (OCUP) - Stock Titan
RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup - Yahoo Finance
Opus Genetics Advances New Gene Therapy Trial for Rare Childhood Blindness - TipRanks
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell 2500 Growth Benchmark - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell 2000 Index - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell 2000 Growth Benchmark - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell 3000E Growth Benchmark - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell Microcap Index - marketscreener.com
Opus Genetics, Inc.(NasdaqCM: IRD) added to Russell 3000E Index - marketscreener.com
Enterprise value to EBIT forward of Opus Genetics, Inc. – NASDAQ:IRD - TradingView
Enterprise value to EBIT forward of Opus Genetics, Inc. – DUS:R3X1 - TradingView
Opus Genetics Shares Rise on Addition to Russell Indexes - Moomoo
Opus Genetics, Inc. Actuals & Estimates (NASDAQ:IRD) - TradingView
Opus Genetics to join Russell 2000 and Russell 3000 indexes - Investing.com UK
Opus Genetics, Inc. Actuals & Estimates (FWB:R3X1) - TradingView
IRD Forecast — Price Target — Prediction for 2027 - TradingView
A2QG4Z Forecast — Price Target — Prediction for 2027 - TradingView
Opus Genetics to join Russell 2000 and Russell 3000 indexes By Investing.com - Investing.com Nigeria
Opus Genetics Inc (IRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):